Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines

Title
Combining Milatuzumab with Bortezomib, Doxorubicin, or Dexamethasone Improves Responses in Multiple Myeloma Cell Lines
Authors
Keywords
-
Journal
CLINICAL CANCER RESEARCH
Volume 15, Issue 8, Pages 2808-2817
Publisher
American Association for Cancer Research (AACR)
Online
2009-04-08
DOI
10.1158/1078-0432.ccr-08-1953

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now